Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

77 results about "Anti inflammatory treatment" patented technology

Anti-inflammatory treatment is defined as NASIDs, COX-2 inhibitors, pro-inflammatory cytokine inhibitors and Minocycline hydrochloride.

Diarylheptanoid compounds in curcuma zedoary and medicinal application thereof

The invention belongs to the technical field of medicines and discloses new diarylheptanoid compounds extracted and separated from Guangxi curcuma zedoary and application thereof in the field of medicines. The chemical structure of the diarylheptanoid compounds is determined by spectrum technology such as a high resolution mass spectrum, one-dimensional and two-dimensional nuclear magnetic resonance spectrum and the like, and a chemical method. The diarylheptanoid compounds can be combined with a pharmaceutically acceptable carrier to prepare clinically acceptable medicines for anti-inflammatory treatment. Experiments for inhibiting lipopolysaccharide-induced rat macrophage from synthesizing nitric oxide (NO) in vitro prove that: the diarylheptanoid compounds have high activity of inhibiting the nitric oxide from being generated, and can be used as anti-inflammatory medicines for preventing and / or treating human and animals.
Owner:SHENYANG PHARMA UNIVERSITY

Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease

InactiveUS20050032673A1Promote multimerizationPrevents its cross-linking activityPeptide/protein ingredientsMammal lectinsDiseaseBinding site
There is provided a composition for anti-cancer or anti-inflammatory treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating disease by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3, its homologues, antibody to galectin-3 carbohydrate binding sites, or a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Further, there is provided a disease treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier.
Owner:MANDALMED

Injectable self-curing artificial bone repair material and preparation method thereof

The invention relates to an injectable self-curing artificial bone repair material and a preparation method thereof. The preparation method comprises the following steps: preparation of two-phase calcium phosphate porous particles, preparation of mineralized collagen porous calcium phosphate composite material and mixing with calcium sulfate hemihydrate. The prepared artificial bone repair material has the following characteristics that: (a) the mineralized collagen is uniformly distributed on the surface and the pores of the two-phase calcium phosphate porous particles, so that the mineralized collagen is uniformly combined with the porous calcium phosphate, thereby having better biocompatibility; (b) the material has a porous structure, not only is favorable for the growth of the bone tissue and the creeping substitution, but also has certain supporting strength; (c) the material can be used as a carrier for growth factors and various antibiotics to carry out anti-inflammatory treatment; (d) the material can be developed under X-ray, which facilitates inspection; (e) the material is degradable, which avoids secondary pain resulting from taking out, and the rate of degradation maybe matched with the new bone growth rate; (f) the material can be injected in situ and has excellent self-curing properties.
Owner:BEIJING ALLGENS MEDICAL SCI & TECH

Marine fungus-derived naphthoquinone compound and anti-inflammatory application thereof

The invention discloses a marine fungus-derived naphthoquinone compound and anti-inflammatory application thereof. A marine fungus Diaporthe sp.GZU-1021 is obtained through separation and purification, and preserved in the Guangdong General Microbiological Culture Collection Center (GDMCC), and the preservation number is GDMCC No: 60601. The strain can secrete the brand-new naphthoquinone compound, and the compound has the effect of remarkably inhibiting generation of LPS-induced NO and has the clinical application potential for anti-inflammatory treatment. Therefore, the naphthoquinone compound has good application prospects and wide development space in preparation of anti-inflammatory drugs.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Method and composition for treating osteoarthritis

A method and composition for treating osteoarthritis including administering an anti-inflammatory agent to a patient, wherein the anti-inflammatory agent is ethyl (α-guanido-methyl) ethanoate. Ethyl (α-guanido-methyl) ethanoate provides a safe, non-toxic anti-inflammatory treatment for osteoarthritis.
Owner:VIREO SYST

Immunostimulatory Method

ActiveUS20120277293A1Organic active ingredientsAntipyreticNucleotideCG-dinucleotide
Methods for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition who does not respond or responds poorly or inadequately to steroid anti-inflammatory treatment or a steroid dependent patient afflicted with an inflammatory condition and currently on steroid anti-inflammatory treatment who shows an inability to be weaned off systemic or topical administered steroid treatment comprise administering an oligonucleotide having the sequence 5′-Xm-CG-Yn-3′ wherein X is A, T, C, or G, Y is A, T, C, or G, m is 1-20 and n is 1-20, or the sequence 5′-CG-3′ and from 8 to 40 nucleotides, wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is administered in an amount effective to improve sensitivity of the patient to the steroid anti-inflammatory treatment and thereby induce a clinical response in the steroid refractory patient or improve a clinical response in the steroid dependent patient.
Owner:INDEX PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products